Table 1. Patient characteristics and results of univariate analysis using CTCAE & Chang grading as ordinal outcomes.
| CTCAE | P value** | Chang | P value** | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 (n =26) |
1 (n=8) |
2 (n=41) |
3 (n=35) |
4 (n=6) |
0 (n=31) |
1a (n=17) |
1b (n=15) |
2a (n=5) |
2b (n=10) |
3 (n=32) |
4 (n=5) |
|||
| Age (years) | ||||||||||||||
| Median | 7.73 | 12.78 | 8.80 | 4.94 | 3.95 | 0.010 | 8.49 | 9.66 | 8.80 | 4.41 | 6.43 | 5.24 | 4.04 | 0.040 |
| Range | 0.59-17.67 | 0.83-18.60 | 0.80, 18.18 | 0.62, 17.15 | 1.17, 10.05 | 0.69, 18.03 | 1.98, 18.18 | 0.80, 18.60 | 1.22, 14.02 | 1.20, 17.15 | 0.62, 15.98 | 1.17, 10.05 | ||
| Ethnicity | ||||||||||||||
| Caucasian | 23(22.8%) | 7 (6.9%) | 33(32.7%) | 33(32.7%) | 5 (5.0%) | 0.45 | 27(27.0%) | 13(13.0%) | 12(12.0%) | 4 (4.0%) | 9 (9.0%) | 31(31.0%) | 4 (3.0%) | 0.62 |
| Other | 3 (25.0%) | 0 (0.0%) | 6 (50.0%) | 2 (16.7%) | 1 (8.3%) | 3 (25%) | 3 (25%) | 2 (16.7%) | 1 (8.3%) | 1 (8.3%) | 1 (8.3 %) | 1 (8.3%) | ||
| Gender | ||||||||||||||
| Male | 17 (23.0%) | 6 (8.1%) | 32(43.2%) | 15(20.3%) | 4 (5.4%) | 0.030 | 22(30.1%) | 10(13.7%) | 13(17.8%) | 4 (5.5%) | 7 (9.6%) | 14(19.2%) | 3 (4.1%) | 0.089 |
| Female | 9 (21.4%) | 2 (4.8%) | 9 (21.4%) | 20(47.6%) | 2 (4.8%) | 9 (21.4%) | 7 (16.7%) | 2 (4.8%) | 1 (2.4%) | 3 (7.1%) | 18(42.9%) | 2 (4.8%) | ||
| Cumulative cisplatin dose in mg/m2 | ||||||||||||||
| Median | 344 | 317.0 | 480 | 320 | 260 | 0.023 | 350 | 480 | 480 | 400 | 440 | 280 | 280 | 0.012 |
| Range | 60-600 | 240-560 | 208-560 | 180-560 | 100-800 | 60-600 | 208-560 | 240-560 | 280-480 | 216-516 | 180-560 | 100-800 | ||
| Cranial Irradiation | ||||||||||||||
| YES | 3 (7.5%) | 2 (5.0%) | 16(40.0%) | 17(42.5%) | 2 (5.0%) | 0.028 | 4 (10.0%) | 5 (12.5%) | 6 (15.0%) | 3 (7.5%) | 4(10.0%) | 16(40.0%) | 2 (5.0%) | 0.048 |
| NO | 23 (30.3%) | 6 (7.9%) | 25(32.9%) | 18(23.7%) | 24(5.3%) | 27(35.5%) | 12(15.8%) | 9 (11.8%) | 2 (2.6%) | 6 (7.9%) | 16(21.0%) | 3 (4.0%) | ||
| Vincristine | ||||||||||||||
| YES | 9 (14.3%) | 2(3.17%) | 22(34.9%) | 25(39.7%) | 5(7.94%) | 0.0091 | 10(15.9%) | 8 (12.7%) | 7 (11.1%) | 3 (4.8%) | 5 (7.9%) | 25(39.7%) | 4 (6.4%) | 0.012 |
| NO | 17 (32.1%) | 6(11.3%) | 19(35.8%) | 10(18.9%) | 1(1.89%) | 21(39.6%) | 9 (17.0%) | 8 (15.1%) | 2 (3.8%) | 5 (9.4%) | 7(13.2%) | 1 (1.9%) | ||
| Carboplatin* | ||||||||||||||
| YES | 2 (9.52%) | 0 (0%) | 8 (38.1%) | 10(47.6%) | 1(4.76%) | 0.097 | 2 (9.52%) | 2 (9.52%) | 3 (14.3%) | 0 (0%) | 1(4.76%) | 11(52.4%) | 1(4.76%) | 0.076 |
| NO | 24 (25.3%) | 8(8.42%) | 33(34.7%) | 25(26.3%) | 5(5.26%) | 29(30.5%) | 15(15.8%) | 12(12.6%) | 5 (5.26%) | 9(9.47%) | 21(22.1%) | 4(4.21%) | ||
Data are presented as number (%) of patients, or median with range (minimum, maximum), unless otherwise indicated. Analysis is of the worse ear if asymmetric hearing loss present. Cumulative cisplatin dose is measured in mg/m2.
*
Carboplatin YES refers to patients who cisplatin and carboplatin as part of the same treatment protocol. NO refers to patients who were not exposed to carboplatin whilst they were also treated with cisplatin. Patients in the latter group may have been changed from cisplatin to carboplatin therapy during their treatment.
**
p-value from multinomial logistic regression model.